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ABSTRACT 60 
Background and objectives: Antihypertensive treatment with calcium channel blockers (CCBs) is 61 
consolidated in clinical practice, however different studies observed increased risks of acute events for short-62 
acting CCBs. This study aimed to provide real-world evidence on risks of acute CV events, hospitalizations 63 
and mortality among users of different CCBs classes in secondary CV prevention.  64 
Methods: Three case-control studies were nested in a cohort of Italian elderly hypertensive CV-65 
compromised CCBs users. Cases were subjects with CV events (n=25,204), all-cause hospitalizations 66 
(n=19,237), or all-cause mortality (n=17,996) during the follow-up. Up to 4 controls were matched for each 67 
case. Current or past exposition to CCBs at index date was defined based on molecule, formulation and daily 68 
doses of the last CCBs delivery. The odds ratio (OR) and 95% confidence intervals was estimated using 69 
conditional logistic regression models.   70 
Results: Compared to past users, current CCBs users had significant reductions in risks of CV events (OR 71 
0.88 [95%CI: 0.84 – 0.91]), hospitalization (0.90 [0.88 – 0.93]) and mortality (0.48 [0.47 –  0.49]). Current 72 
users of long-acting dihydropyridines (DHPs) had the lowest risk (OR 0.87 [0.84 – 0.90], 0.86 [0.83 – 0.90], 73 
0.55 [0.54-0.56] for acute CV events, hospitalizations and mortality), whereas current users of short-acting 74 
CCBs had an increased risk of acute CV events (OR 1.77 [1.13– 2.78] for short-acting DHPs; 1.19 [1.07 – 75 
1.31] for short-acting non-DHPs) and hospitalizations (OR 1.84 [0.96 – 3.51] and 1.23 [1.08 – 1.42]).  76 
Conclusions: The already-existing warning on short-acting CCBs should be potentiated, addressing 77 
clinicians towards the choice of long-acting formulations.  78 
 79 
KEY POINTS 80 
• Real world evidence on CCBs risks of acute events among CV-compromised hypertensive elderly was 81 
provided; 82 
• Current use of CCBs significantly reduced risks of CV events, hospitalizations and mortality; 83 
• Current use of short-acting CCBs was associated with higher risks of acute events; clinicians should 84 
be addressed towards choice of long-acting formulations.  85 
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1. INTRODUCTION 86 
Arterial hypertension affects 33% and 31% of men and women in Italy, with an increasing trend in 87 
prevalence, mainly due to population aging [1]. Arterial hypertension is considered an independent, 88 
modifiable risk factor for the occurrence of major cardiovascular (CV) events; what’s more, the majority of 89 
hypertensive patients suffer from additional CV pathologies or risk factors, which further potentiate the risk 90 
of acute CV events and mortality [2].  91 
Therefore, the pharmacological management of hypertension is strongly recommended. Among 92 
antihypertensive treatments, use of calcium channel blockers (CCBs) is well established in clinical practice, 93 
either in primary or secondary CV prevention. According to their chemical structure and to their rapidity of 94 
action onset, CCBs can be divided into 4 main classes: short-acting dihydropyridines (DHPs); long-acting 95 
DHPs; short-acting non-DHPs CCBs (n-DHPs); and long-acting n-DHPs.  96 
Despite their recognized [3-5] efficacy , the CV safety of CCBs, and in particular of rapid-onset 97 
formulations, has been long debated.  98 
Since 1995, different studies correlated CCBs, and in particular short-acting nifedipine (a DHP CCB), with 99 
an increased risk of overall mortality and CV events [6-8]. In light of these findings, current Beers criteria 100 
classify short-acting nifedipine as an inappropriate drug for elderly patients [9]. 101 
Despite this, short-acting nifedipine and rapid-onset CCBs in general are still used in clinical practice, also in 102 
elderly subjects at high CV risk.  103 
Given this discrepancy, the present study aimed to provide evidence from the Italian real clinical practice on 104 
the risks of acute CV events, all-cause hospitalizations and mortality connected to the different CCBs 105 
classes, focusing on a wide population of hypertensive CV-compromised elderly. This study was part of a 106 
large program supported by the Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE), 107 
aimed to assess the appropriateness of outpatient drug prescriptions in the Italian elderly discharged from 108 
hospital for CV diseases.   109 
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2. SUBJECTS AND METHODS 110 
2.1. Study design 111 
Three case-control studies were nested into a cohort of elderly hypertensive patients diagnosed with CV 112 
diseases. The three studies aimed to evaluate the risk of acute CV events (study 1), all-cause hospitalizations 113 
(study 2) and mortality (study 3) among current vs past CCBs users. 114 
To limit the possible indication bias, a user-only approach was adopted in all studies, excluding all 115 
hypertensive patients never prescribed with CCBs [10].  116 
 117 
2.2. Setting 118 
The setting of this study and the methodology for data retrieval have been previously described [11, 12].   119 
Briefly, all data used for the present study were retrieved from the healthcare utilization databases of 3 120 
Italian Regions (Lazio, Lombardy and Tuscany) and 2 Local Health Authorities (Caserta and Treviso), 121 
participating to the I-GrADE program.  122 
About 21 million beneficiaries residing in these areas were recorded in the corresponding databases of 123 
healthcare services, providing information on nearly 35% of the Italian population. 124 
Administrative databases consulted for this study included: i) an archive of demographic and 125 
administrative data of residents who receive National Health Service (NHS) assistance; ii) a database on 126 
hospital discharge records including information about primary diagnosis and up to five co-existing 127 
conditions and procedures (secondary diagnosis fields) coded according to the International Code of 128 
Disease, 9th revision (ICD-9 CM) classification system; iii) a prescription database providing information 129 
on all community prescriptions reimbursed by the NHS with drugs coded according to the Anatomical 130 
Therapeutic Chemical (ATC) classification system. Each subject is identified through a unique 131 
identification code, therefore allowing the record linkage among databases. In order to preserve privacy, 132 
the original unique identification code was replaced with its digest that is the image of the code through a 133 
cryptographic hash function.  134 
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2.3. Participants 135 
Beneficiaries of the NHS who i) were residing in the participating healthcare territorial units, ii) were 136 
aged 65 years or older, and iii) had been hospitalized with a diagnosis of selected CV diseases in the years 137 
2008-2010 (considering ICD9-CM codes reported in Supplementary material S1 text, in primary or 138 
secondary diagnosis field), were considered eligible to enter the cohort. The date of the first CV-related 139 
hospitalization in the period was considered as the entry date in the study. Subjects were excluded if they 140 
i) were discharged dead from the entry hospitalization, ii) had history of malignancies (identified from a 141 
discharge diagnosis with ICD9-CM codes 140*-208* in primary or secondary diagnosis) at any time prior 142 
to the entry date, and/or iii) did not have at least 2 years of uninterrupted observation prior to the entry 143 
date. Of the remaining patients, only subjects that i) had a diagnosis of hypertension (identified from a 144 
discharge diagnosis with ICD-9 CM code 401* in primary or secondary diagnosis fields) in the 2 years 145 
before the entry date, and ii) had at least one prescription of a CCBs (ATC codes C08* or C09BB* or 146 
C09DB*) following the entry date, were included in the final cohort. 147 
For study 1 and 2, members accumulated person-years of follow-up from the first date of CCBs delivery 148 
after the entry date, until the occurrence of: i) a further acute CV events, ii) a hospitalization with a 149 
diagnosis of cancer, iii) death, and/or iv) end of data availability. For study 3, instead, members 150 
accumulated person-years of follow-up until: i) a hospitalization with a diagnosis of cancer, ii) death, 151 
and/or iii) end of data availability.  152 
The first date among these events were considered as exit date. Patients who exit the study in the 15 days 153 
following the entry date were excluded, since death or re-hospitalizations were probably related to the 154 
entry hospitalization rather than to a new event.  155 
2.4. Definition of case subjects and controls 156 
Cases were defined as subjects experiencing the outcome of interest during follow-up: CV-related 157 
hospitalization in study 1, identified considering the ICD9-CM coded reported in Supplementary material 158 
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S2 text; all-cause hospitalizations in study 2; all-cause mortality in study 3. For each case subject, the first 159 
date of the outcome of interest was defined as the index date. 160 
Each case was matched to up to 4 controls randomly selected by risk-set sampling from all cohort 161 
members whose follow-up did not end prior to the index date of the corresponding case. Matching was 162 
performed within each participating healthcare territorial unit according to gender, age, and month and 163 
year of entry in the study. Of note, a subject could be considered as a case subject in one study and as a 164 
control in the other studies. Cases with no matched controls were excluded from the study.  165 
2.5. Exposure to CCBs 166 
To evaluate whether or not subjects were currently exposed to CCBs at time of index date, the last prescription 167 
of CCBs during the follow-up was considered. The amount of defined daily doses (DDD) of the last CCB 168 
delivery was considered. A grace period corresponding to the 20% of the amount of the last DDD delivered 169 
was given. Patients currently exposed to CCBs at time of index date were considered as current users; on the 170 
other hand, patients without CCBs therapeutic coverage at index date were considered as past users. For current 171 
users, exposition to the four different CCBs classes was assessed considering the CCB active principle and 172 
formulation: long-acting DHP, including amlodipine alone (C08CA01) or in combination with perindopril 173 
(C09BB04) or with olmesartan medoxomil (C09DB02), felodipine alone (C08CA02) or in combination with 174 
ramipril (C09BB05), isradipine (C08CA03), nimodipine (C08CA06), nisoldipine (C08CA07), nitrendipine 175 
(C08CA08), lacidipine (C08CA09), manidipine alone (C08CA11) or in combination with delapril (C09BB12), 176 
barnidipine (C08CA12), lercanidipine alone (C08CA13) or in combination with enalapril (C09BB02), and 177 
release-modified formulation of nicardipine (C08CA04) and nifedipine (C08CA05); short-acting DHP, 178 
including not release-modified formations of nifedipine (C08CA05) and nicardipine (C08CA04); long-acting 179 
n-DHPs, including gallopamil (C08DA02), and release-modified formulations of verapamil (C08DA01) or 180 
diltiazem (C08DB01); short-acting n-DHP, including not release-modified formulations of verapamil 181 
(C08DA01) and diltiazem (C08DB01). 182 
 183 
2.6. Covariates 184 
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Covariates assessed for each case and control included: i) use to CCBs in the 6 months before the entry in the 185 
study; v) severity of the CV disease, assessed considering the occurrence of cardiovascular procedures in the 186 
2 years before entry in the study, identified as reported in Supplementary material S3 text; vi) type of CV 187 
pathology at entry (identified as reported in Supplementary material S1 text); vii) Charlson Comorbidity 188 
Index (CCI), calculated in the 2 years before the entry date according to the algorithm reported by Quan et al. 189 
[13], and categorized as 0, 1, or ≥ 2; viii) current use of other antihypertensive treatment at time of index 190 
date. 191 
2.7. Data analysis 192 
Percentages of all considered covariates among cases and controls were compared using Chi-square tests. A 193 
conditional logistic regression model for matched case-control data was used to estimate the Odds Ratio 194 
(OR), and 95% confidence interval (CI), of the outcomes of interest associated with current use of CCBs 195 
compared with past use. Adjustments were made for the above listed covariates.  196 
All analyses were performed using the software STATA version 14. For all tested hypotheses, two-tailed p-197 
values less than 0.05 were considered statistically significant. 198 
2.8. Sensitivity analyses 199 
A sensitivity analysis was performed to limit the possible unmeasurable bias coming from CCBs 200 
deliveries occurred during a hospital stay [14]. In fact, drug deliveries occurring during hospitalizations 201 
are not recorded in administrative databases. With this aim, cohort members who experienced 202 
hospitalization for whichever cause in the 30 days before index date were excluded.  Sensitivity analysis 203 
was performed only for study 1 and 3.  204 
  205 
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3. RESULTS 206 
An initial cohort of 965,903 subjects discharged from a CV-related hospitalization was extracted 207 
(Figure 1). Following the application of the defined exclusion criteria, a final cohort of 107,533 208 
hypertensive elderly affected by CV pathologies and treated with CCBs was selected. 209 
27,679 subjects experienced a further acute CV event: of them, 2,475 were excluded due to lack of 210 
matching controls. 25,204 patients were included as cases subjects and were matched to 55,325 211 
controls (study 1). All-cause hospitalizations occurred instead in 74,488 out of the 107,533 subjects: of 212 
them, 55,251 were excluded due to lack of matching controls. 19,237 cases and 20,102 matching 213 
subjects were included in study 2.  All-cause death occurred in 22,080 patients, of whom 4,084 were 214 
excluded due to lack of matching controls. 17,996 were included as cases subjects and were matched 215 
to 45,431 controls (study 3).  216 
3.1. Characteristics of cases and controls 217 
Table 1 provides some selected characteristics of cases and controls included in the three studies. 218 
According to matching variables (study design), cases were comparable to controls in all studies. 219 
Considering the CV disease at entry, more cases than controls were diagnosed with heart failure or 220 
cardiac arrhythmia in all studies, with ischemic heart disease in study 1 and 3, and with stroke in study 3. 221 
As concern CV procedures, more cases than controls had undergone coronary artery bypass surgery and 222 
other heart surgery procedures in study 1 and 2, percutaneous transluminal coronary angioplasty in study 223 
2, and cerebral revascularization in study 1. Based on CCI, case subjects were frailer than controls in all 224 
studies.  In all studies, use of CCBs in the 6 months before entry was more frequent among cases. On the 225 
other hand, current use of CCBs at index date was more frequent among controls in all studies.    In 226 
particular, in all three studies, more controls than cases were currently exposed to long-acting DHPs. On 227 
the other hand, in all studies, current use of short-acting DHPs was more frequent among case subjects. 228 
As concerning n-DHPs CCBs, current use of either long- or short-acting formulations was significantly 229 
higher among cases than controls in study 1 and 2, while it was higher among controls in study 3.  230 
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Focusing on other antihypertensive treatments currently used at index date, diuretics were more used 231 
among cases than controls in all studies, beta-blockers were more used among controls in study 3, agents 232 
acting on the Renin-Angiotensin system were more used among controls in study 2 and 3, and other anti-233 
hypertensive drugs (ATC code C02*) were more used among cases in study 1 and 2, and among controls 234 
in study 3. 235 
3.2. Use of CCBs and risks of acute CV events, all-cause hospitalizations and mortality 236 
The effect of CCBs on the risk of acute CV events, all-cause hospitalizations and mortality is shown in 237 
Figure 2. Focusing on acute CV events, current users of CCBs exhibited a risk reduction of 12% (OR 238 
0.88 [95% CI: 0.84-0.91]) compared to past CCBs users. In particular, stratifying according to the 239 
different CCBs classes, only long-acting DHPs were associated with a significant reduction in risk (OR 240 
0.87 [0.84 – 0.90]); on the other hand, current users of either short-acting DHPs or n-DHPs resulted to be 241 
at increased risk of acute CV events (OR 1.77 [1.13 – 2.78] and 1.19 [1.07 – 1.31]), respectively). 242 
The occurrence of the different CV outcomes among current users of the different CCBs classes is 243 
reported in Figure 3.  The most frequent CV outcome was cardiac arrhythmia, which was experienced by 244 
10.74% of current CCBs users, followed by heart failure (6.61%), ischemic stroke (5.77%), acute 245 
myocardial infarction (4.52%), transient ischemic attack (1.62%) and haemorrhagic stroke (0.90%). Of 246 
note, occurrence of acute myocardial infarction, cardiac arrhythmia and heart failure was significantly 247 
higher among current users of short-acting DHPs compared to long-acting DHPs (p<0.05). Similarly, 248 
occurrence of cardiac arrhythmia and heart failure was significantly higher among current users of short-249 
acting n-DHPs compared to long-acting n-DHPs (p<0.05), whereas the occurrence of acute myocardial 250 
infarction was significantly higher among users of long-acting n-DHPs (p<0.05).  251 
Focusing on all-cause hospitalizations, current use of CCBs resulted to play a protective role compared to 252 
past use (OR 0.90 [0.88 – 0.93]) (Figure 2). Stratifying according to CCBs classes, only long-acting 253 
DHPs were associated with a significant reduction in risk (OR 0.88 [0.83 - 0.90]). On the other hand, both 254 
long- and short-acting n-DHPs were associated with an increased risk of hospitalizations (OR 1.15 [1.04 – 255 
1.27] and 1.23 [1.08 – 1.42]).  256 
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Considering all-cause mortality, current CCBs users exhibited a risk reduction of 52% (OR 0.48 [0.47-257 
0.49]) compared to past CCBs users. In particular, all CCB classes except short-acting DHPs were 258 
associated with a significant reduction in risk (OR of 0.55 [0.54 – 0.58] for long-acting DHPs; 0.62 [0.58 259 
– 0.66] for long-acting n-DHPs; 0.83 [0.75 – 0.91] for short-acting n-DHPs).  260 
3.3. Sensitivity analysis 261 
In the sensitivity analysis of study 1, 11,672 case subjects who experienced acute CV events where 262 
matched to 22,543 controls. Results of this analysis confirmed a protective role of current use of CCBs 263 
towards acute CV events (OR 0.89 [0.85 – 0.92]) (Supplementary Table S1). In particular, current users 264 
of long-acting DHPs were at the lowest risk (OR 0.87 [0.84 – 0.91]), whereas current users of either 265 
short-acting DHPs or n-DHPs were at significantly higher risk (OR 1.75 [1.32 – 2.31] and 1.17 [1.07 – 266 
1.28], respectively).  In the sensitivity analysis of study 3, 8,427 case subjects who died for whichever 267 
cause were matched to 20,394 controls. Current users of CCBs resulted to be at significantly lower risk of 268 
mortality (OR 0.40 [0.38 – 0.43]). In particular, current exposition to all CCBs classes, except short-269 
acting DHPs, resulted to be protective towards all-cause mortality.  270 
  271 
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4. DISCUSSION 272 
In this large population-based study of elderly hypertensive patients formerly experiencing a major CV 273 
hospital admission, we found that current use of CCBs significantly decrease the risk of both 274 
hospitalizations (for acute CV events or for whichever cause) and mortality, compared to past CCBs use. 275 
In particular, current users of long-acting DHPs were found to be at the lowest risk of all considered 276 
events. Our results add further evidence supporting the effectiveness of CCBs in secondary CV 277 
prevention, therefore highlighting the importance of a strict adherence to this treatment.  278 
On the other hand, we found that current users of either short-acting DHPs or n-DHPs were at 279 
significantly higher risk of hospital admission for both acute CV events and all causes, compared to past 280 
CCBs users.  281 
The increase in risks connected to the use of short-acting CCBs could be attributable to the rapid 282 
mechanism of action of these formulations, which may lead to severe blood pressure fluctuations, 283 
unpredictable episodes of severe hypotension, and to tachycardia [15]. Our findings are consistent with 284 
previous evidences showing an increased risk of death and acute CV events in patients exposed to rapid-285 
onset CCBs in secondary CV prevention. Already in 1995, a first meta-analysis on 16 randomized 286 
secondary-prevention trials on nifedipine was published, reporting a dose-related increased risk of overall 287 
mortality among patients exposed to short-acting nifedipine (risk ratio of 1.16 [95% CI: 1.01 to 1.33] [6].  288 
Later on, another meta-analysis on 60 randomized controlled trials evaluated the risk of CV event in 289 
patients affected by stable angina and treated with nifedipine in mono- or combination therapy compared 290 
to control patients treated with other active drugs in monotherapy [7]. Treatment with immediate-release 291 
nifedipine was found to significantly increase the risk of angina (OR of 4.19 [95% CI: 1.41 to 12.49]) as 292 
well as of all events combined (OR of 3.09 [95% CI: 1.39 to 6.88].  293 
More recently, a case-crossover study was conducted on 16,069 elderly hypertensive patients 294 
experiencing a first stroke events; a significant increase in both ischemic and haemorrhagic stroke 295 
associated to the use of short-acting nifedipine was reported (OR 2.56 [95% CI: 1.89–3.47] and 5.16 296 
[95% CI: 2.29–11.66], respectively) [8]. 297 
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Despite the well-known risk associated to short-acting CCBs, we found that rapid-onset CCBs were still 298 
in use in the real clinical practice, although the design of this study did not allow to estimate the entity of 299 
the overall population exposed to these formulations. However, considering the CV burden and the old 300 
age of the study population, antihypertensive treatment with short-acting DHPs was probably 301 
inappropriate in these patients.   302 
Comparing current use of long-acting formulations of DHPs vs n-DHPs, we found that n-DHPs were 303 
associated with higher risk of all considered outcomes. However, this difference in safety profile is likely 304 
to be ascribable more to patients’ related characteristics than to the molecules themselves, given the 305 
differences in therapeutic indications among these two drug classes [16].  306 
Our study included a large and unselected cohort of CCBs users aged 65 years or older with a 307 
hospitalization for major CV events and diagnosed with hypertension. This means that our findings can 308 
be generalised only to elderly suffering of CV disease and elected for an antihypertensive treatment with 309 
CCBs in secondary CV prevention. All eligible patients were included, so no bias due to non-response 310 
was present, and no recall bias occurred because data on their characteristics (including drug use) were 311 
recorded before the outcomes occurred. The drug prescription database provided highly accurate data, 312 
because pharmacists are required to report prescriptions in detail in order to obtain reimbursement, and 313 
incorrect reports about the dispensed drugs have legal consequences. In addition, the user-only design 314 
adopted in this study allowed to control for possible indication bias coming from variability in indications 315 
of use of CCBs [10, 14]. Finally, the performed sensitivity analyses confirmed the data provided by the 316 
main analysis.  317 
However, our study has limitations. First, results of blood pressure monitoring were not available in our 318 
data sources; occurrence of CV events, as well as of all-cause hospitalizations and death, could be 319 
therefore related to a non-response to antihypertensive treatment, rather than to the anti-hypertensive 320 
drug. Second, no information was available on the current health and CV condition of subjects: current 321 
users of CCBs (and in particular of short-acting formulations) at time of index date could have been 322 
prescribed with short-acting CCBs, following the onset of a CV complication not recorded on 323 
administrative databases.  Third, evaluation of CCBs use was based on pharmacy-dispensing information. 324 
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This method assumes that prescription corresponds to medication use, which may not be invariably true. 325 
Although data on dispensing history have shown to be consistent with other adherence measures [17], 326 
medication dispensing as a measure of drug use remains a source of uncertainty of our estimates. Fourth, 327 
both comorbidities and events were retrieved based on ICD9-CM codes; however, problems related to 328 
incomplete or wrong coding may be present. In addition, 329 
ICD-9-CM codes do not indicate degree of severity. Fifth, less than 0.5% of the entire considered 330 
population was exposed to short-acting DHPs at time of index date; therefore, results concerning this drug 331 
class could be influenced by the small size of this sample. Finally, as for any observational study, residual 332 
confounding linked for example with unmeasured disease severity, comorbidity, socio-economic status 333 
and various lifestyle factors, cannot be fully eliminated.  334 
  335 
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5. CONCLUSION 336 
Although suffering from the above-mentioned limitations, our study provided key information from the real 337 
clinical practice on the effectiveness of antihypertensive treatment with long-acting CCBs as well as on the 338 
possible risk associated with short-acting CCBs formulations. Since any potential increased risk may result in 339 
a considerable public health impact, the risk estimates of short-acting CCBs provided by this study may support 340 
both clinical practitioners and regulatory activities. From our point of view, the already-existing warning on 341 
short-acting CCBs should be potentiate, addressing clinicians towards the choice of long-acting formulations.  342 
 343 
 344 
  345 
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FIGURE LEGENDS 393 
 394 
Fig. 1 Flow-diagrams of the three user-only nested case-control studies 395 
CCB= Calcium Channel Blockers; CV= Cardiovascular 396 
 397 
Fig. 2 Risks of acute cardiovascular events, hospitalizations and mortality for current vs past users of the 398 
different Calcium Channel Blockers classes 399 
CCB= Calcium Channel Blockers; CI= Confidence Intervals; CV= Cardiovascular; DHPs= 400 
Dihydropyridines; n-DHPs=non- Dihydropyridines; OR= Odds Ratio 401 
 402 
Fig. 3 Occurrence of the acute CV outcomes in exam among users of the different Calcium Channel 403 
Blockers classes 404 
CCB= Calcium Channel Blockers; DHPs= Dihydropyridines; n-DHPs=non- Dihydropyridines 405 
 406 
